Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Glioblastoma Multiforme Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The glioblastoma multiforme market has experienced significant expansion in recent years. It is anticipated to grow from $2.7 billion in 2025 to $2.92 billion in 2026, exhibiting an 8.1% compound annual growth rate (CAGR). The historical growth of this market can be attributed to several factors including limited treatment options, advancements in neuro-oncology, standardization of chemotherapy, the expansion of cancer research centers, and improvements in imaging technologies.
The glioblastoma multiforme market is projected to experience substantial growth in the coming years. It is anticipated to expand to $3.94 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.8%. This expansion during the forecast period is primarily driven by the development of novel targeted drugs, the broadening of immunotherapy research, the adoption of personalized cancer treatment, increased funding for brain cancer research, and an enhanced focus on improving survival outcomes. Significant trends for the forecast period include a heightened emphasis on targeted cancer therapies, the increasing application of multimodal treatment approaches, the advancement of precision oncology research, the wider integration of advanced imaging diagnostics, and improved participation in clinical trials.
Get A Free Sample Report With In-Depth Market Insights:
Glioblastoma Multiforme Market Demand Drivers: What’s Powering Industry Growth?
The glioblastoma multiforme market is projected to be propelled forward by the increasing incidence of brain disorder cases. A brain disorder is defined as a condition that affects the brain’s structure or function, resulting in cognitive, emotional, or physical deficits. The growing number of brain disorder cases stems from factors such as an aging demographic, longer life expectancies, various lifestyle factors, and improved diagnostic capabilities. A deeper comprehension of brain disorders is crucial for progressing research into glioblastoma multiforme (GBM), paving the way for better early detection, novel treatments, and enhanced patient outcomes. By investigating neurological conditions, researchers can identify genetic and molecular connections relevant to GBM’s development. For instance, in February 2025, according to Dementia Australia, an Australia-based non-profit organization, approximately 433,300 Australians are living with dementia, with this number expected to rise to 812,500 by 2054. Additionally, younger-onset dementia affects around 29,000 people in 2025, with projections indicating an increase to 41,000 by 2054. Therefore, the escalating prevalence of brain disorders will stimulate the growth of the glioblastoma multiforme market.
Glioblastoma Multiforme Market Segment Analysis Spotlighting Growth Areas
The glioblastoma multiforme market covered in this report is segmented –
1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools
3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types
4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites
2) By Temozolomide: Branded (Temodar), Generic Temozolomide
3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine), Generic Lomustine
5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy
Glioblastoma Multiforme Market Innovation Trends Shaping Future Development
Prominent companies operating in the glioblastoma multiforme market are focusing on the development of advanced therapies, such as CAR T-cell therapies, to address the pressing unmet medical needs of this aggressive cancer. CAR T-cell therapies represent a form of immunotherapy that involves modifying a patient’s T-cells to more effectively target and eliminate cancer cells. As an illustration, in June 2023, Chimeric Therapeutics Limited, an Australia-based biotech firm, launched a Phase IB clinical trial for its CHM 1101 (CLXT CAR T) therapy, aimed at recurrent or progressive glioblastoma multiforme (GBM). This multi-center trial seeks to evaluate the therapy’s safety and efficacy while also establishing the recommended Phase 2 dose. Initial Phase 1a results indicated disease stability, and the current trial will expand on these findings to support further development. The company plans to use the collected data to design a registration trial and to obtain regulatory feedback.
Glioblastoma Multiforme Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.
View The Full Glioblastoma Multiforme Market Report:
Glioblastoma Multiforme Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the glioblastoma multiforme market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
